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A B S T R A C TObjective: To estimate the cost-effectiveness of enhancing ad
herence to blood pressure (BP)-lowering drug therapy in a large
population without signs of preexisting cardiovascular (CV) disease.
Methods: A cohort of 209,650 patients aged 40 to 79 years resident in
the Italian Region of Lombardia and newly treated with BP-lowering
drugs during 2000 to 2001 was followed from index prescription to
2007. During the follow-up, the 10,688 patients who experienced a
hospitalization for a coronary or cerebrovascular event were identified
(outcome). Adherence was measured by the proportion of days
covered by the therapy with BP-lowering drugs. The cost-
effectiveness of enhancing adherence was measured through the
incremental cost-effectiveness ratio. Results: Enhancing adherence
from 52% (baseline) to 60% and 80% led to a reduced rate for CV
outcomes (from 85 to 83 and 77 events every 10,000 person-year,see front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2012.11.008
.corrao@unimib.it.
ondence to: Giovanni Corrao, Department of Statis
degli Arcimboldi, 8, 20126 Milan, Italy.respectively) and increased the cost for drug therapy (from h1,325k to
h1,507k and h1,934k every 10,000 person-year, respectively). The
resulting incremental cost-effectiveness ratio decreased from h76k
(95% confidence interval h74k–h77k) to h74k (95% confidence interval
h72k–h75k) for each CV event avoided by enhancing adherence from
baseline to 60% and 80%, respectively. Conclusions: Enhancing adher-
ence to BP-lowering medications in the setting of primary CV
prevention might offer important benefits in reducing the risk of CV
outcome, but at a substantial cost.
Keywords: adherence, administrative database, blood pressure–lowering
drugs, cardiovascular events, cost-effectiveness.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Randomized clinical trials have consistently shown that hyper-
tension is a reversible risk factor; that is, a reduction in elevated
blood pressure (BP) induced by pharmacological treatments
reduces the risk of fatal and nonfatal cardiovascular (CV) events
[1]. It is also well known, however, that effective BP reduction is
rare in the hypertensive population [2–5], and in individuals with
uncontrolled BP, the incidence of CV events is higher than among
patients who have achieved BP control [6]. Evidence shows 1) very
low adherence to BP-lowering medication in the setting of daily
clinical practice [7,8], 2) that poor adherence to antihypertensive
medication is related to lack of BP control [9], and 3) that there is
a relationship between adherence to BP-lowering drugs and the
risk of CV outcomes [10–15].
These findings suggest that interventions aimed at increasing
adherence to BP-lowering agents would be effective in achieving
full benefits from drug treatment [16]. However, interventions ofthis type necessarily lead to an increment in the overall costs
because of increased drug use. This is particularly important
from the public health perspective because the economic
resources available are limited and it is important to allocate
them in the best way to maximize the level of population health
[17]. It is, therefore, suitable to jointly evaluate cost and effec-
tiveness of the treatment to quantify the additional cost needed
to increase the effectiveness of treatment-related enhanced
adherence. To the best of our knowledge, no such evaluation
has been carried out in the setting of primary prevention of CV
outcomes and using BP-lowering drug therapy.
We estimated the cost-effectiveness of enhancing adherence
to BP-lowering drug therapy in a large population without signs
of preexisting CV disease in the setting of primary CV prevention.
Costs and effectiveness were estimated from a population-based
cohort study. Data were derived from an administrative database
monitoring the use of health services of the population residing
in the Lombardia region (Italy).Society for Pharmacoeconomics and Outcomes Research (ISPOR).
tics, Unit of Biostatistics and Epidemiology, University of Milano-
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Setting
The data used for the present study were retrieved from the
health care service databases of Lombardia, a region of Italy that
accounts for about 16% (9 million) of its population. In Italy,
health care is provided by the National Health Service (NHS). In
Lombardia, this has been associated since 1997 with an auto-
mated system of databases to collect a variety of data, including:
1) an archive of residents who receive NHS assistance (effectively
the whole resident population), including demographic and
administrative data; 2) a hospital discharge database providing
data on diagnoses recorded for each admission in a public or
private hospital of the region; and 3) a database of outpatient
drug prescriptions reimbursable by the NHS; this includes data
on Anatomical Therapeutic Chemical (ATC) code and the corre-
sponding amount of active drug for each prescription dispensed
by a pharmacy of the region.
For each patient we linked the above databases by using a single
identification code. To preserve privacy, each identification code
was automatically converted to an anonymous code. The inverse
process was prevented by the deletion of the conversion table. Full
details of the procedure have been reported elsewhere [18].
Study Cohort and Follow-Up
The Lombardia residents who were beneficiaries of the NHS and
were aged 40 to 79 years represented the target population.
According to the 2001 Italian Census, this population comprised
4,341,438 individuals. Among them, we identified those who
received at least one BP-lowering drug prescription at any time
from January 1, 2000, to December 31, 2001. The first drug
prescription was defined as the index prescription. The drugs
considered belonged to all the available BP-lowering drug classes,
that is, agents acting on alpha-adrenergic receptors (ATC code
C02), diuretics (ATC code C03), beta-blockers (ATC code C07),
calcium channel blockers (ATC code C08), and agents acting on
the renin-angiotensin system (ATC code C09), dispensed either as
monotherapy or as a fixed-dose or extemporaneous combination
of two or more drugs.
To make the data as relevant as possible to the study aim, four
categories of patients were excluded from data analysis: 1)
patients who had received at least one BP-lowering drug pre-
scription within 3 years before the index prescription, to ensure
the inclusion of newly treated individuals only; 2) patients who
had been hospitalized for CV disease or who had received a
prescription of drugs used for coronary heart disease or heart
failure (e.g., digitalis and organic nitrates) in the 3 years preced-
ing the index prescription, to focus the data on primary CV
prevention; 3) patients who did not reach at least 1 year of follow-
up, to ensure at least 1 year of potential exposure to the drugs of
interest; and 4) patients who had received only one BP-lowering
drug prescription during the first year after the date of index
prescription, based on the assumption that continuous drug
treatment might not have been indicated for these patients.
Each member of the cohort accumulated person-years (PY) of
follow-up from the date of index prescription until the first-ever
hospital admission for CV disease or the end of the study period
(December 31, 2007). Individuals who transferred out of the
region or died during follow-up were censored.
Assessment of Adherence to BP-Lowering Drug Therapy
All prescriptions dispensed to each cohort member during the
follow-up were used to measure the cumulative exposure to
BP-lowering drugs. Starting from the index prescription, thenumber of days with drug available was calculated by dividing
the total amount of active drug dispensed at each prescription by
the recommended defined daily dose. In this way, each day in the
follow-up period was labeled as ‘‘covered’’ or ‘‘not covered’’ by
drug availability, regardless of whether availability concerned
single or combined prescriptions. Adherence was measured by
dividing the cumulative number of covered days by the number
of days of follow-up, a measure denoted as proportion of days
covered (PDC) [19,20]. PDC was categorized into the following four
levels: very low (r25%), low (26%–50%), intermediate (51%–75%),
and high adherence (475%).
Outcome
Data on hospital discharge were used to identify cohort members
who experienced a hospitalization for coronary or cerebrovascu-
lar (major CV) event during the follow-up. The WHO-MONICA
criteria for the ascertainment of coronary and cerebrovascular
events were followed [21,22]. Coronary events included those
related to acute myocardial infarction, acute or subacute types of
ischemic heart disease, and interventions of coronary revascu-
larization. Cerebrovascular events included those related to sub-
arachnoid hemorrhage, intracerebral hemorrhage, unspecified
intracranial hemorrhage, occlusion of cerebral arteries, acute
cerebrovascular disease, and surgical interventions on intra- or
extracranial head or neck vessels. The occurrence of at least one
of these events was sufficient for a patient to be considered as
experiencing the outcome; the earliest date of hospital admission
recording one of these events was considered as the time of the
outcome onset.
Other Factors
The type of drug regimen at the index date (monotherapy or a
combination of two or more drugs as first-line BP-lowering
therapy) and the number of BP-lowering classes used during
the follow-up were recorded. Drugs used for heart failure or
coronary heart disease (i.e., digitalis glycosides and organic
nitrates), lipid-lowering agents, other CV drugs, and antidiabetic
medications dispensed to each cohort member during the follow-
up were also recorded. In addition, the Charlson comorbidity
index [23] was calculated by using diagnostic information from
inpatient visits in the 3 years prior to and 1 year after the index
date. The index was summarized by using two categories (i.e., 0
or 1, respectively, suggesting the absence or presence of at least
one comorbidity factor).
Estimating the Relationship between Adherence and Outcome
A time-to-event analysis was undertaken by using the Cox
proportional hazards model to estimate the hazard ratio (HR),
and the corresponding 95% confidence interval (CI), for the
association between adherence to BP-lowering drug therapy
and the time of outcome occurrence. The predictor variables of
interest were the dummy factors constructed according to the
categories of PDC, using very low adherence as the reference
category. Estimates were adjusted for factors measured at base-
line (such as age, gender, antihypertensive drug regimen, and
Charlson comorbidity index) as well as during follow-up (i.e.,
number of BP-lowering classes and cotreatments with CV and
antidiabetic drugs during follow-up). Because adherence, as well
as all the other factors measured during follow-up, can change
over time, the assessment of their effects requires properly
accounting for the time-varying nature of these variables. This
was done by fitting a Cox model that includes these factors as
time-dependent covariates [24]. For instance, by considering the
predictor variables of interest (i.e., the dummy factors of PDC),
each subject’s cumulative adherence is recalculated from the
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Thus, the HR associated with a category of PDC is derived by
using information updated at the time of each observed outcome.
The same approach was used for the other time-varying factors
mentioned above.
The methods described above have been reported in detail in
an article investigating the adherence-outcome relationship,
authored by our group [15]. What was not investigated by our
previous article was the cost-effectiveness profile of enhancing
adherence. The next section describes in detail the methods used
for answering this question, which represents the main objective
of the current study.
Estimating the Cost-Effectiveness Profile of Enhancing
Adherence
Starting from the observed average PDC (baseline), three scenar-
ios were built by progressively enhancing the average level of
adherence to 60%, 70%, and 80%. For each scenario, we calculated
the decreased number of CV events with respect to the baseline
and the corresponding cost of drug therapy as follows.
First, we considered the distribution of PY of follow-up over
the categories of PDC observed at baseline and that expected for a
given scenario. The expected distribution of PY of follow-up was
computed from the expected PDC value for each patient obtained
by adding to his or her observed coverage a random value drawn
from a two-sided truncated normal distribution [25], with mean
and variance equal to the difference between the average PDC at
baseline and that imposed by the scenario.
Then, we estimated the average annual incidence rate of
hospitalization for major CV events at baseline and that expected
for a given scenario. The baseline rates over the PDC categories
were computed from the incidence rate observed among patients
with very low adherence and the HRs obtained from the Cox
model. The annual number of hospitalizations for major CV
events expected for a given scenario was computed by applyingFig. 1 – Flowchart of inclusion and exclusion critthe baseline rates over the PDC categories at the corresponding
expected distribution of PY of follow-up. The annual number of
hospitalizations for major CV events that would be avoided by
increasing adherence at the level imposed by a given scenario
was estimated as the difference between the observed and
expected number of CV events.
Next, we computed the average annual cost for BP-lowering
drug therapy observed at baseline and that expected for each
given scenario. Observed costs were measured from the perspec-
tive of the Italian NHS by using the amount that the Regional
Health Authority reimbursed pharmacies for dispensing drugs.
With reference to drug price in the year 2009, the average daily
cost for treating a patient in our setting was h0.62, ranging from
h0.07 to h0.90 for therapy with the generic diuretic chlortalidone
to the combination of the angiotensin receptor antagonist can-
desartan with the diuretic hydrochlorothiazide, respectively. The
expected drug costs were estimated for the expected distribution
of PY of follow-up over the categories of PDC, assuming that the
prescription profile does not change when increasing adherence.
The average annual incremental drug cost due to the increased
use of drugs was estimated as the difference between the
observed cost with baseline PDC and that expected for a given
scenario.
Finally, by comparing each scenario with the baseline, we
computed the incremental cost-effectiveness ratio (ICER) [26] as
the ratio between the incremental drug cost (in h) and the
number of CV hospitalizations avoided. According to the proce-
dure described above, the ICER must be interpreted as the
additional annual drug cost that would be borne by the NHS to
avoid one hospitalization for a major CV event every year, as a
consequence of enhancing adherence at a certain level among
new users of BP-lowering drugs without established CV disease.
Because the distribution of ICER is unknown, we used a
nonparametric bootstrap method to account for the underlying
uncertainty [27]. The 2.5th and the 97.5th percentiles of the boot-
strap distribution were used to calculate the 95% CI for the ICER.eria. BP, blood pressure; CV, cardiovascular.
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culating the ICER under the assumption that during follow-up all
patients are treated with the BP-lowering drug at the lowest cost
among those available in the therapeutic class in which the
treatment begun. Accordingly, the average daily cost in this
situation was h0.075 (ranging from h0.069 to h0.41 for monother-
apy with diuretics or a fixed combination of angiotensin receptor
antagonist and diuretics, respectively).
For all the hypotheses tested, two-tailed P values less than
0.05 were considered as significant.
The analyses were performed by using SAS software version
9.1.3 (SAS Institute, Inc., Cary, NC).Results
Inclusion and exclusion criteria are shown in Figure 1. The
209,650 patients included in the study accumulated 1,244,870
PY of follow-up (on average 6 years per patient) and 653,394 PY of
treatment with BP-lowering drugs (on average 52% of the time of
follow-up was spent with drug available). The cohort generated
10,688 first hospitalizations for a major CV event; with an
incidence rate of 86 cases every 10,000 PY.
Table 1 summarizes some selected characteristics of the
whole cohort and by adherence to statin therapy. The average
age at entry was 60  10 years, and 45% of the patients were men.
Most patients started BP-lowering therapy with one agent only,
but during the follow-up the majority of them received at least
three BP-lowering classes. About 44% of the patients received at
least once another drug for preventing or treating CV events
during follow-up. Comorbidities, ascertained by a Charlson
comorbidity index of more than 1, were present in about 13% ofTable 1 – Selected characteristics of the included patients
BP-lowering drugs.
Very low
(n ¼
45,755)
Low
(n ¼
47,374)
Length of follow-up (y), mean  SD 5.77  1.49 5.91  1.45
Age (y), mean  SD 58.9  10.8 60.2  10.5
Male gender, n (%) 17,248 (37.7) 19,733 (41.7)
Initial BP-lowering drug regimen, n (%)
Monotherapy 31,759 (69.4) 32,728 (69.1)
Combination of two or more drugs 13,996 (30.6) 14,646 (30.9)
No. of BP-lowering classes used during follow-up, n (%)
1 17,078 (37.3) 9,978 (21.1)
2 15,052 (32.9) 14,553 (30.7)
Z3 13,625 (29.8) 22,843 (48.2)
Users of other drugs during follow-up, n (%)
Drugs used in diabetes 5,133 (11.2) 6,261 (13.2)
Lipid-lowering drugs 10,233 (22.4) 12,727 (26.9)
Digitalis glycosides/organic
nitrates 4,323 (9.4) 5,421 (11.4)
Other cardiac drugs 5,112 (11.2) 5,917 (12.5)
Charlson comorbidity index, n (%)z
0 40,402 (88.3) 41,073 (86.7)
Z1 5,353 (11.7) 6,301 (13.3)
BP, blood pressure.
 Adherence was measured according to the proportion of days of obser
following: very low coverage (r25%), low coverage (26%–50%), intermedi
y P values obtained from chi-square test or F test (length of follow-up an
z Measuring the extension of comorbidity from inpatient encounters inthe included patients. Overall, 44% of the patients had very low or
low adherence to BP-lowering drugs, and only 26% had high
adherence. Compared with patients who had high adherence,
those with a very low or low adherence were mainly women,
were initially treated with a combination of two or more BP-
lowering drugs, received a minor number of BP-lowering classes
during follow-up, and had a better profile of cotreatments and
comorbidities.
The association between adherence to BP-lowering drug
therapy and the risk of hospitalization for major CV event is
shown in Figure 2. Compared with patients with very low
adherence level, those with low, intermediate, and high adher-
ence, respectively, showed HR of 0.95 (95% CI 0.90–1.01), 0.76 (95%
CI 0.72–0.81), and 0.72 (95% CI 0.68–0.76).
Figure 3 shows the trends in the number of hospitalizations
for major CV events and cost for drug treatment (upper box), and
in the ICER (lower box), from baseline to any scenarios of
enhanced adherence. The number of patients experiencing a
hospitalization for major CV event decreases from 85.41 events
every 10,000 PY observed at baseline to 83.03, 80.08, and 77.14
events every 10,000 PY, respectively, for 60%, 70%, and 80%
average level of adherence. Conversely, the cost for drug therapy
increases from the observed value of h1,324,727 at baseline to
h1,506,759, h1,724,770, and h1,933,440 every 10,000 PY, respec-
tively, for 60%, 70%, and 80% average level of adherence. The
estimates for the ICER and the corresponding 95% CI were h76,484
(h74,807–h78,152), h75,055 (h73,490–h76,623), and h73,605
(h72,180–h75,157) for each hospitalization for a major CV event
avoided by enhancing the average level of adherence from base-
line to 60%, 70%, and 80%, respectively. The corresponding values
of the ICER were h25,400, h25,300, and h25,200 if all patients were
treated with the less expensive drug in each therapeutic class.according to categories of adherence to therapy with
Adherence level Py
Intermediate
(n ¼ 61,389)
High
(n ¼
55,132)
Total
(n ¼
209,650)
6.03  1.35 6.00  1.35 5.94  1.41 o.0001
60.0  9.9 59.4  9.5 59.6  10.1 o.0001
27,654 (45.0) 28,663 (52.0) 93,298 (44.5) o.0001
44,598 (72.6) 42,805 (77.6) 151,890 (72.5) o.0001
16,791 (27.4) 12,327 (22.4) 57,760 (27.6)
8,275 (13.5) 7,651 (13.9) 42,982 (20.5) o.0001
16,105 (26.2) 13,670 (24.8) 59,380 (28.3)
37,009 (60.3) 33,811 (61.3) 107,288 (51.2)
9,253 (15.1) 9,899 (18.0) 30,546 (14.6) o.0001
18,764 (30.6) 17,839 (32.4) 59,563 (28.4) o.0001
7,090 (11.6) 5,747 (10.4) 22,581 (10.8)
o.0001
7,552 (12.3) 6,085 (11.0) 24,666 (11.8) o.0001
53,163 (86.6) 46,642 (84.6) 181,280 (86.5) o.0001
8,226 (13.4) 8,490 (15.4) 28,370 (13.5)
vation covered by BP-lowering medication. Adherence levels are the
ate coverage (51%–75%), and high coverage (475%).
d age).
the 3 y prior and 1 y after the index date.
Fig. 2 – Trend in hazard ratios, and corresponding 95%
confidence intervals, for dose-response relationship
between adherence to therapy with BP-lowering drugs and
the risk of developing a cardiovascular outcome. Adherence
to therapy with antihypertensives was assessed by the ratio
between the cumulative number of days during which the
medication was available and the whole number of days of
follow-up (proportion of days covered). This indicator was
categorized into four groups: very low coverage (r25%), low
coverage (26%–50%), intermediate coverage (51%–75%), and
high coverage (475%). Hazard ratios were obtained by
fitting the Cox proportional hazards model. Estimates are
adjusted for gender, age at entry, concomitant use of other
drugs, number of antihypertensive classes dispensed
during follow-up, first-line therapy regimen, and Charlson
comorbidity index. BP, blood pressure.
Fig. 3 – Trends in the distribution in the number of nonfatal
cardiovascular (CV) events and cost for drug therapy (upper
box), and in incremental cost-effectiveness ratio, with
corresponding 95% confidence intervals (lower box), every
10,000 person-year, from baseline to scenarios of
progressively enhancing average adherence to therapy with
BP-lowering drugs. BP, blood pressure.
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Our study confirms previous observations that adherence to
antihypertensive drug treatment is rather low in clinical practice
and that low adherence is associated with increased CV risk
[7,10–15]. This implies that interventions aimed at enhancing
adherence would avoid many hospitalizations for CV outcomes,
even if at a substantial cost. As a novel and original message, we
estimated that about h76k per year would be additionally spent
for every 10,000 subjects initiating antihypertensive therapy to
avoid one hospitalization for a major CV event every year by
means of enhancing the average adherence from 52% (baseline)
to 60%. Costs for avoiding the considered outcome only weakly
decreased by enhancing the average adherence from baseline to
70% (h75k) or 80% (h74k).
Such estimates should be compared with the cost borne by
the Italian NHS for attending to patients affected by major CV
disease. A recent Italian study estimated that the first episode of
acute myocardial infarction has an annual cost of h15k in the first
year and h3.7k in the following years [28]. It has also been
reported that in Germany the costs for hospitalization, drug
prescription, rehabilitation, and nursing are h19k and h43k,
respectively, during the first year and the lifetime after the first-
ever ischemic stroke [29]. At first glance, then, the cost of treating
a major CV event is lower than the cost that should be borne by
preventing one hospitalization for a major CV event by means of
enhancing drug adherence.
At least two considerations need, however, to be further
addressed before drawing conclusions on this subject. First, we
showed that the cost of avoiding a CV hospitalization might be
reduced by up to two third by using less expensive drugs. That is,
adherence-enhancing interventions might be much more cost-
effective by encouraging the use of drugs at lowest cost among
those available in a given therapeutic class, typically generic
drugs. Of course, this is true under the assumption thattreatment with generic antihypertensive drugs does not lead to
lower adherence or more CV disease–related hospitalizations
compared with brand-name therapy [30]. Second, several
patients received only one antihypertensive drug prescription in
our setting. These patients were excluded from our analysis
because continuous drug treatment might not have been indi-
cated for most of them. In fact, we recently showed that these
patients have a better risk profile and lower CV disease incidence
than do those on multiple drug prescriptions [31]. Thus, it is
reasonable to speculate that with respect to patients receiving
multiple prescriptions, most of those on single dispensation have
relatively modest hypertension and nonpharmacological advice
on healthier lifestyles (e.g., cut back on salt, physical exercise,
and smoking cessation) might be the more appropriate indication
for these patients [31]. Whatever the reason, however, only one
dispensation for treating a condition that once properly diag-
nosed requires lifetime treatment undoubtedly represents an
inappropriate allocation of health resources. The burden of this
phenomenon is not negligible because in our setting it accounts
for 65,000 patients and h1,300,000 every year [31]. These resources
might be properly allocated for increasing adherence. Of course,
nonpharmacological advice could have been more indicated than
drug therapy also for a portion of the included patients. However,
we are not able to know the size of this subgroup. Combining
these arguments suggests that the primary prevention of CV
events by enhancing drug adherence might become competitive
with respect to costs of care for patients, provided that less
expensive BP-lowering drugs are dispensed and only those
patients who really need lifetime treatment are subjected to drug
therapy.
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that were made available thanks to the fact that in Italy 1) a cost-
free uniformly organized health care system involves practically
all citizens, 2) the health care system is managed by a set of
databases including inpatients hospital discharge and outpati-
ents drug prescription data, and 3) these databases guarantee
universal coverage of the population receiving health assistance
from the NHS. Consequently, the complete history of health care
utilization of a very large unselected population is available and
real-world clinical practice, including health and economic bur-
den of medical interventions, may be investigated. To the best of
our knowledge, the current study offers unique insight into the
potential of health care utilization database for estimating the
cost-effectiveness profile of medical interventions on hyperten-
sion. Second, we have previously reported that hospital discharge
and drug prescription databases used for the current study
showed a close concordance with either a population-based local
registry of coronary and cerebrovascular events validated accord-
ing to MONICA criteria [32] or data provided by a network of
Italian general practitioners [33]. Finally, a number of sensitivity
analyses previously performed on the same setting as the current
one allowed us to verify the robustness of our findings. For
example, we previously reported that there was no substantial
variation of the adherence-outcome association by using alter-
native PDC categorizations, varying the length of follow-up, using
alternative censoring criteria, and adjusting the estimates for
unmeasured confounders [15,34].
Our study has a number of potential limitations. External
validity (generalizability) of the findings is a first major concern.
The costs for BP-lowering drugs are extremely variable across
countries and are likely to decrease with increasing competition
from generics [35]. Similarly, incidence and mortality for major
CV events is also variable, showing lower values in Italy than in
other Western countries [36]. Finally, with the aim of limiting
sources of heterogeneity of the investigated population by the
inclusion of patients likely affected by comorbidities and cotreat-
ments, individuals aged 80 years or older were excluded from our
analysis. As a consequence, our estimates cannot be universally
generalized.
Both the components of the cost-effectiveness estimate are
likely to be affected by sources of systematic uncertainty. As far
as costs are concerned, our analysis did not include those of
interventions’ implementation. A recent review of studies on
interventions improving adherence to antihypertensive and lipid-
lowering medications identified a variety of different means of
improving adherence [37]. These may be broadly classified as
involving professional input by a doctor, nurse, and/or pharma-
cist or involving patients’ education regarding their therapies.
The most effective approaches for improving adherence were
those based on personalized, intensive interventions closely
monitoring patients’ adherence and involving more than one
visit during follow-up. A general positive relationship between
the estimated cost for intervention implementing and its impact
on improving adherence was also reported. This suggests that
costs of enhancing adherence are likely to be not negligible with
respect to those directly charged for the increased use of drugs.
We are not able, however, to include the costs of implementation,
as well as of the management of hypertension in the population
and of increasing the use of general practitioner time. This is
because to our best knowledge, no studies have been performed
in Italy on this subject. A general worsening of the reported cost-
effectiveness estimates is expected if other cost sources were
taken into account.
As far as measuring effectiveness is concerned, the sources of
uncertainty in measuring the relationship between adherence and
outcome should be carefully considered. First, no information was
available on the diagnosis of hypertension. Thus, the patientsincluded in our study may have had conditions other than hyper-
tension that require BP-lowering drug administration. A recent
study, however, has reported that in Italy hypertension represents
by far the most common diagnosis for the use of antihypertensive
drugs, with only about 20% being used for angina pectoris, myo-
cardial infarction, and heart failure (often associated with hyperten-
sion anyway) and less than 1% for other acute indications, such as
edema [38]. Second, because the data on outcome onset have been
drawn from the hospital discharge archive, our estimates concern
only nonfatal outcomes. Because there is no evidence of hetero-
geneous effects of antihypertensive drugs on the risks of fatal and
nonfatal coronary events [39], however, the selection of nonfatal
outcomes only should not affect the validity of our estimates. Third,
our study does not account for several health benefits that might
derive from enhancing adherence. For example, the treatment may
reduce morbidity for angina, congestive heart failure, and chronic
heart failure, as well as all-cause morbidity and mortality [9–13].
Cost-effectiveness estimates are expected to have a much more
favorable profile than that found in our study, whether these health
benefits of enhancing adherence were also taken into account.
Fourth, adherence with treatment was derived from drug prescrip-
tions, which is the most feasible and widely used method to
estimate compliance in large populations [7]. With this method,
however, the assumption has to be made that the PDC by a
prescription corresponds to the proportion of days of drug use,
which may not be invariably the case. Because misclassification of
exposure is expected to be independent from the disease status, the
reduction of CV risk associated with high levels of adherence might
be larger than that quantified here [40]. If this was true, adherence-
enhancing interventions would become even more cost-effective.
Finally, because the allocation to levels of adherence to BP-lowering
drugs was not randomized, the results of our study may be affected
by confounding. Even if we attempted to limit confounding by
adjustment for some demographic, therapeutic, and clinical factors,
higher adherence could still be a surrogate for other unmeasured
characteristics. The so-called healthy adherer effect might occur by
assuming that healthier patients are more likely to adherer to
therapy [41]. It should be taken into account, however, that patients
with worse clinical profile (i.e., those affected by chronic comorbid-
ities and on treatment for hyperlipidaemia and diabetes) are, on the
one hand, at higher CV risk; however, on the other hand, these
patients more frequently adhered to BP-lowering therapy than did
thosewith a better clinical profile. This finding is consistent with the
existing literature [10] and suggests that the protective effect of
adherence on the CV risk, and consequently the benefits in enhan-
cing adherence, might be larger than that estimated by our study if
the difference in clinical profiles over the strata of adherence was
taken into account.
All these potential limitations taken together suggest that out
findings are indicative of only the direction, rather than the exact
magnitude, of the trends in costs and effectiveness among
scenarios of enhancing adherence.
In conclusion, our results confirm that the management of
hypertension is unsatisfactory in the general practice because of
quite low level of treatment adherence. Our approach based on
both real-world drug utilization and hospital discharge informa-
tion supplies evidence that interventions for enhancing adher-
ence might offer important benefits in reducing the risk of
hospitalization for major CV outcomes, although with a substan-
tial cost. Important resources saving might be obtained by
encouraging the use of less expansive medications, such as
generic drugs, and by discouraging the waste of resources for
the treatment of patients who do not need drug therapy. In turn,
this would free resources to finance interventions of enhancing
adherence. While the final decision on the sustainability of the
cost-related improvement of therapeutic adherence rests on the
Regional Health Authority, we believe that the interventions
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 1 8 – 3 2 4324discussed here have potential and should be considered by public
health decision makers.
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